前列腺MRI PI-RADS v2评分与根治性局部治疗后生化复发风险的预后关联:系统综述与Meta分析
该系统综述与Meta分析评估前列腺MRI PI-RADS v2评分与前列腺癌根治性局部治疗后生化复发(BCR)风险的关联。纳入9项系统综述研究(2,274例)和7项Meta分析研究(1,215例),其中8项为根治性前列腺切除术背景。根治性前列腺切除术后,较高PI-RADS v2评分与BCR风险显著相关(合并HR 3.06,95%CI 2.16-4.33;p<0.01),所有研究中合并HR为3.19(95%CI 2.28-4.45;p<0.01)。
要点
- 根治性前列腺切除术后,较高PI-RADS v2评分与BCR风险显著相关(合并HR 3.06)。
- 所有纳入研究中,PI-RADS v2评分与BCR风险仍显著相关(合并HR 3.19)。
- 前列腺MRI PI-RADS v2分类具有独立于诊断之外的预后价值。
核心结论
- 前列腺MRI PI-RADS v2分类与根治性局部治疗后BCR风险独立相关,主要基于根治性前列腺切除术数据。
- 研究结果支持MRI除诊断作用外还具有预后意义。
研究设计与样本
- 系统综述纳入9项研究共2,274例患者,Meta分析纳入7项研究共1,215例患者。
- 8项研究在根治性前列腺切除术背景下进行,1项在放疗后背景下进行。
- 评估偏倚风险和质量后,进行正式Meta分析估计前列腺MRI分类对BCR风险的合并效应。
主要发现
- 根治性前列腺切除术患者中,较高PI-RADS v2评分与BCR风险显著相关(合并HR 3.06,95%CI 2.16-4.33;p<0.01)。
- 研究间无显著异质性。
- 所有研究中,PI-RADS v2评分仍与BCR显著相关(合并HR 3.19,95%CI 2.28-4.45;p<0.01)。
关键数值与推荐
- 根治性前列腺切除术患者:较高PI-RADS v2评分与BCR风险相关,合并HR 3.06(95%CI 2.16-4.33;p<0.01)。
- 所有研究:PI-RADS v2评分与BCR风险相关,合并HR 3.19(95%CI 2.28-4.45;p<0.01)。
临床怎么用
- 前列腺MRI PI-RADS v2评分可用于根治性局部治疗后BCR风险分层。
- PI-RADS v2评分应作为前列腺癌诊断之外预后评估的参考信息。
局限性
- 主要基于根治性前列腺切除术数据,仅1项研究为放疗后背景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although the Prostate Imaging-Reporting and Data System™ version 2 (PI-RADS™ v2) is a reliable diagnostic tool for significant prostate cancer, less is known about the prognostic significance of the structured reporting scheme for estimating oncologic outcomes after treatment. We aimed to synthesize the available evidence regarding the association of PI-RADS v2 score and risk of biochemical recurrence (BCR) among patients undergoing primary definitive treatment for prostate cancer. MATERIALS AND METHODS: We systematically queried the PubMed® and Web of Science™ databases to identify studies addressing the association between the PI-RADS v2 and treatment outcomes. We included studies through November 2020 that assessed the independent prognostic significance of PI-RADS v2. After assessing risk of bias and quality, we conducted a formal meta-analysis to estimate the pooled effects of prostate magnetic resonance imaging (MRI) classification on the risk of BCR. RESULTS: We identified 9 and 7 eligible studies including 2,274 and 1,215 patients for the systematic review and meta-analysis, respectively. Eight were conducted in the context of radical prostatectomy and 1 post-radiation. Among patients treated with radical prostatectomy, higher PI-RADS v2 scores were significantly associated with risk of BCR (pooled HR 3.06, 95% CI 2.16-4.33; p <0.01). There was no significant heterogeneity among studies. For all studies, PI-RADS v2 score remained significantly associated with BCR (pooled HR 3.19, 95% CI 2.28-4.45; p <0.01). CONCLUSIONS: Prostate MRI findings assessed with the PI-RADS v2 classification were independently associated with risk of BCR after definitive local therapy, primarily based on data from radical prostatectomy. These findings support the prognostic significance of MRI, in addition to its role in prostate cancer diagnosis.
引用
- Rajwa P, Mori K, Huebner NA, et al. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. J Urol. 2021. PMID: 33904755. doi:10.1097/JU.0000000000001821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。